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AbstrACt
Introduction Hepatitis C virus (HCV) infection affects 
0.7% of the general population, and up to 40% of people 
prescribed opioid substitution therapy (OST) in Scotland. In 
conventional care, less than 10% of OST users are tested 
for HCV and less than 25% of these initiate treatment. 
Community pharmacists see this group frequently to 
provide OST supervision. This study examines whether a 
pharmacist-led ‘test & treat’ pathway increases cure rates 
for HCV.
Methods and analysis This protocol describes a cluster-
randomised trial where 60 community pharmacies provide 
either conventional or pharmacy-led care. All pharmacies 
offer dried blood spot testing (DBST) for HCV. Participants 
have attended the pharmacy for OST for 3 months; are 
positive for HCV genotype 1 or 3; are not co-infected with HIV 
and/or hepatitis B; have no decompensated liver disease; 
are not pregnant. For conventional care, pharmacists refer 
HCV-positive participants to a local centre for assessment. 
In the pharmacy-led arm, pharmacists assess participants 
themselves in the pharmacy. Drug prescribing is by nurse 
prescribers (conventional arm) or pharmacist prescribers 
(pharmacy-led arm). Treatment in both arms is delivered 
as daily modified directly observed therapy in a pharmacy. 
Primary trial outcome is number of sustained virological 
responses at 12 weeks after treatment completion. Secondary 
trial outcomes are number of tests taken; treatment uptake; 
completion; adherence; re-infection. An economic evaluation 
will assess potential cost-effectiveness. Qualitative research 
interviews with clients and health professionals assess 
acceptability of a pharmacist-led pathway.
Ethics and dissemination This protocol has been 
ethically approved by the East of Scotland Research 
Ethics Committee 2 (15/ES/0086) and complies with the 
Declaration of Helsinki and principles of Good Clinical 
Practice. Caldicott guardian approval was given on 16 
December 2016 to allow NHS Tayside to pass information 
to the cluster community pharmacies about the HCV test 
status of patients that they are seeing to provide OST 
supervision. NHS R&D approvals have been obtained 
from each health board taking part in the study. Informed 
consent is obtained before study enrolment and only 
anonymised data are stored in a secured database, 
enabling an audit trail. Results will be submitted to 
international peer-reviewed journals and presented at 
international conferences.
trial registration number NCT02706223; Pre-results.
bACkground 
Hepatitis C is a bloodborne viral infection 
causing liver disease. Around 0.7% of the 
Scottish population are chronically infected 
with hepatitis C virus (HCV).1 Patient 
outcomes from HCV infection vary, with 25% 
clearing the infection spontaneously and the 
remainder becoming chronically infected, 
risking development of cirrhosis and hepato-
cellular carcinoma.2 A recent Public Health 
England report highlighted that less than half 
of those infected with HCV have been iden-
tified, and of those identified less than 3% 
of those known to be infected with HCV are 
being treated.3 The greatest risk of acquiring 
the virus in the UK is through injecting drug 
use4 and evidence suggests around 40% of 
strengths and limitations of this study
 ► Real world study developed using the Medical 
Research Council guidelines on complex 
interventions.
 ► Potential to provide answers to an extremely topical 
question around approaches to eliminate a disease, 
in line with a WHO target.
 ► Uses community pharmacy-based pathway in 
the National Health Service Scotland, but not wider 
primary care systems.
 ► Relies on close and integrated working between a 
specialist hepatitis service and community pharma-
cy services.
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people in Scotland receiving opioid substitution therapy 
(OST) have HCV infection.5 Only a small proportion of 
this high-risk and vulnerable population are receiving 
adequate treatment, despite having daily healthcare inter-
action with a pharmacist and the availability of a curative 
intervention with widely available direct-acting antiviral 
(DAA) medication.6 
The conventional care pathway in the UK recommends 
that patients with a history of intravenous drug use, 
or those currently prescribed OST, should be offered 
HCV testing annually.3 Testing may be available from 
their GPs, drug workers, drug agencies, social workers, 
community pharmacies and needle exchanges.7 Once 
diagnosed, patients can be referred to established 
treatment pathways, usually based around hepatology 
teams in secondary care. In these established treat-
ment pathways, less than 10% of the OST population 
is tested for HCV annually. Of those tested, at most 
25% start treatment in one of the dedicated centres 
and 70%–80% successfully complete treatment, with 
treatment failure primarily caused by non-adherence 
and non-persistence to treatment.8 Similar patterns are 
observed in other countries.9 The inefficiency of estab-
lished treatment pathways leads to increased prevent-
able deaths from HCV and viral transmission within the 
injecting population.10
A variety of reasons may explain the low rates of 
HCV testing, treatment uptake and treatment comple-
tion. People who inject drugs (PWID) may encounter 
a number of barriers that prevent them from accessing 
care, including perceptions and experience of stigma and 
discrimination, issues with the organisation of care, and 
the treatment policies of providers or payers.11 There 
are identified deficiencies in the extent of screening 
and diagnosis of at-risk populations, as well as the need 
to simplify pathways to enable treatment initiation and 
clinical monitoring.12 PWID may find it difficult to consis-
tently attend medical clinics.13
WHO has set an ambitious goal to eliminate HCV as a 
public health threat by 2030.14
Creating the complex interventions necessary to erad-
icate HCV requires that well-designed cross-disciplinary 
programmes are put in place using different strategies 
to increase screening, testing and diagnosis.15 Strate-
gies that demonstrate increased testing and treatment 
uptake include the provision of integrated HCV care 
pathways with drug use and psychiatric services delivered 
by a multidisciplinary team and with case management 
services.16 The delivery of HCV testing and treatment 
through community-based care pathways has also been 
shown to be feasible and DBST has been demonstrated 
to increase the uptake of testing from high-risk popula-
tions.17 Hence, a more central role in the treatment of 
HCV for community-based pharmacists who are seeing 
these clients on a daily basis, could—in theory—lead to 
increased HCV treatment success rates through higher 
HCV testing, treatment uptake, adherence and treatment 
completion rates.
In preparation for the current trial investigating the clin-
ical benefits of pharmacy-delivered HCV treatment, pilot 
work was undertaken guided by the Medical Research 
Council theoretical framework for developing and eval-
uating complex interventions.18 Initial work involved 
using a co-production approach in partnership with OST 
patients. This work identified the current experiences 
of patients in accessing HCV testing and treatment and 
in accessing OST in pharmacies.19 The attributes of an 
ideal service were identified and an estimate of potential 
uptake made.20 The implementation of DBST in pharma-
cies was undertaken and the experiences of patients and 
providers recorded.21 A pilot trial has been undertaken 
to test each stage of the pharmacy-led care pathway and 
to look for confirmation that an appropriately powered 
definitive multicentre randomised controlled trial would 
be feasible.22 The PRagmatic Explanatory Continuum 
Indictor Summary (PRECIS-2) tool was used to assess that 
the design decisions were concordant with the purpose of 
the trial (online supplementary file 1).23
The aim of this research is to examine the impact of 
pharmacy-delivered HCV treatment on HCV treatment 
success rates among OST users. Our research questions 
are:
trial
1. Does a community pharmacist-led HCV treatment 
pathway increase treatment success rates (sustained 
virological response, or SVR) compared with the con-
ventional pathway?
2. Does a community pharmacist-led HCV treatment 
pathway lead to a higher uptake of HCV testing?
3. Does a community pharmacist-led HCV treatment 
pathway lead to a higher uptake and completion of 
HCV treatment?
4. Is adherence and persistence to HCV therapy in the 
pharmacy setting similar to that in the conventional 
pathway?
5. What is the re-infection rate at 12 months after end of 
treatment in all patients with SVR, and for the phar-
macist-led pathway compared with the conventional 
pathway?
Health economics study
6. Is the pharmacist-led pathway potentially a cost-effec-
tive method of testing and treating HCV in people pre-
scribed OST?
Qualitative study
7. Is the pharmacist-led pathway an acceptable way to of-
fer testing and treatment for people prescribed OST 
infected with HCV and are there any unexpected con-
sequences?
MEtHods
design
Super directly observed therapy (DOT)-C is a cluster 
randomised trial of pharmacy-led anti HCV therapy 
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versus conventional care in patients with HCV infection 
attending community pharmacies (table 1). Sixty phar-
macies will be enrolled in this study across five hubs in 
health boards in National Health Service (NHS) Scot-
land. Pharmacies (and thus their patients) participating 
in the trial will be randomly allocated to conventional 
care pathway or the pharmacy-led pathway.
Pharmacies at each site are randomised into two groups: 
conventional care and pharmacist-led care. Randomisa-
tion will be carried out using http://www. randomization. 
com. The subjects are randomised into one block along 
with the number of subjects per block/number of blocks 
and (case-sensitive) treatment labels. The pharmacies in 
each hub provide the level of randomisation, so patient 
allocation is dependent on the pharmacy attended.
Eligibility criteria
Eligible pharmacies are community based, offer DBST 
for HCV by trained pharmacy staff in line with approved 
practice in their particular NHS board and have at least 
30 patients on OST to ensure adequate recruitment. 
Patient inclusion criteria are having HCV PCR positive 
to genotype 1 or 3, OST users and willing to have their 
pharmacists supervise their antiviral drug use. Patient 
exclusion criteria are having another genotype than 1 or 
3, evidence of current or previous decompensated liver 
disease, HIV infection, surface antigen of hepatitis B virus 
(HBV) positive with detectable HBV DNA, aggressive or 
violent behaviour towards the pharmacist, being preg-
nant and not being able to provide informed consent.
Interventions
Medication provided
The anti-HCV treatment provided in both pathways is 
identical:
 ► For HCV genotype one sofosbuvir/ledipasvir for 8 
weeks
 ► For HCV genotype three sofosbuvir/daclatasvir for 12 
weeks
Study site staff training
Staff from each study site will receive training on Good 
Clinical Practice (GCP), quality control, use of study docu-
mentation, ensuring common practice and consenting 
participants. In addition training to establish testing for 
bloodborne viruses is provided and information on hepa-
titis C and its treatment is provided. Staff in the pharma-
cy-led arm are trained on how to interpret laboratory 
bloods and to perform a Fib4 calculation.24
Conventional care pathway
At the start of the pathway pharmacists will opportunisti-
cally discuss HCV infection with their OST patients. The 
pharmacist will record on a screening log which of the OST 
patients attending the pharmacy they have approached. 
Those with unknown HCV status will be offered testing 
using DBST in the pharmacy.25 Patients identified as 
having HCV antibodies will have a post-test discussion 
with the pharmacist. During this discussion the pharma-
cists will obtain informed consent and explain about HCV 
treatment using a standard infographic (online supple-
mentary file 2). Next, the pharmacist will offer them 
referral to the conventional care pathway for assessment 
and treatment at a local treatment centre. Information 
will be provided verbally and by offering standard leaflets 
about HCV. If the patient attends an appointment at one 
of the local treatment centres, a member of the specialist 
hepatitis team will invite the patient to undertake assess-
ment for treatment for HCV. Assessment comprises a 
pretreatment checklist of medical comorbidities, medical 
history and concomitant medication to look for drug-
drug interactions. The patient will undergo phlebotomy 
in the local treatment centre to check full blood count, 
urea and electrolytes, liver function testing, including 
Table 1 Treatment pathways: similarities and differences
Conventional care Pharmacy pathway Contrast
HCV testing Opportunistic HCV testing on 
presentation for OST therapy
Opportunistic HCV testing on 
presentation for OST therapy
The same procedure is provided in each 
of the study arms
HCV test 
confirmation
Test result is communicated and—if 
positive—referred for assessment in 
local treatment centre
Test result is communicated and—
if positive—assessment directly 
undertaken in the pharmacy
Assessment for treatment is carried out 
at the pharmacy when the participant 
visits to obtain OST, not at a different 
site with a different provider
Treatment 
initiation
Suitable patients are prescribed 
treatment by a nurse prescriber at 
the local treatment centre and access 
treatment through DOT at their 
pharmacy
Suitable patients are prescribed 
treatment by a pharmacist prescriber 
and access treatment through DOT at 
their pharmacy
Treatment initiation is carried out at the 
pharmacy and not at a different site with 
a different provider
Treatment 
monitoring
Treatment monitoring is carried out by 
the specialist team in their clinic
Treatment monitoring is carried out at 
the pharmacy
Treatment monitoring is carried out at 
the pharmacy, not at a different site. 
Monitoring in the conventional pathway 
requires additional clinic visits
Treatment 
completion
SVR testing is carried out by DBST at 
the pharmacy
SVR testing is carried out by DBST at 
the pharmacy
The same procedure is provided in each 
of the study arms
DBST, dried blood spot testing; DOT, directly observed therapy; HCV, hepatitis C virus; OST, opioid substitution therapy; SVR, sustained 
virological response. 
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markers of liver fibrosis24 (Fib4, APRI, AST:ALT ratio) 
and viral parameters (genotype and load), as assessment 
for treatment. Patients who are referred for assessment 
and treatment will be managed according to the stan-
dard local treatment pathway. Daily supervised OST treat-
ment is delivered by the pharmacy, in which the doses 
of methadone or buprenorphine are provided by the 
pharmacy staff, who observe consumption. In both arms 
of the study DAA treatment is delivered jointly with OST 
in their normal pharmacy; which would qualify as DOT 
during weekdays, although at weekends patients usually 
self-administer. Prescriptions will be provided by a nurse 
prescriber and dispensed at the participant’s normal 
pharmacy. For doses that patients have to self-administer 
and the weekend doses when there is no OST distribu-
tion, the pharmacist and patient will make a brief if-then 
action plan (an implementation intention) and coping 
plan (to overcome anticipated barriers).26 The study-re-
lated data collection will be undertaken by the specialist 
hepatitis team.
Pharmacist-led pathway
Potential participants are offered testing, recruited and 
consented as in the conventional pathway. In the phar-
macy-led pathway however, the pharmacist will offer 
them anti-HCV therapy delivered solely within the phar-
macy. The patients who decline study participation will 
be entered in the screening log. For the patients who do 
consent, the pharmacist will complete a pretreatment 
checklist of medical comorbidities, medical history and 
concomitant medication to look for drug-drug interac-
tions. The patient will undergo phlebotomy in the phar-
macy for safety blood tests, as in the conventional pathway 
and the pharmacist will assess this information to deter-
mine suitability for treatment.
If there are no contraindications to therapy, the 
patient will commence the treatment. In patients where 
there are contraindications or queries about suitability, 
the pharmacist will contact the central clinical coordi-
nator for advice. The pharmacist-led pathway requires 
an assessment which includes identification of concur-
rent specific medical conditions, screening of safety 
bloods, calculation of a Fib-4 score, assessment of inter-
acting concurrent medication and assessment of factors 
likely to impinge on treatment compliance. Potential 
participants with a FIB-4 score of >3.25 are referred on 
to the conventional care pathway for review. The phar-
macist-led pathway therefore excludes this group from 
being entered into the trial. Instead, they are assessed for 
treatment through the conventional care pathway where 
they are reviewed in hospital by a medical consultant 
who decides if it is safe to proceed with treatment and, 
if yes, may select different drugs. Unsuitable patients 
are therefore referred to the conventional pathway for 
assessment outside the study and provided with standard 
clinical care. Prescriptions for treatment will be provided 
by a pharmacist prescriber.
Each time that patients pick up their medication from 
the pharmacy a daily log is completed recording any 
occurrence of side effects or adverse events (AEs).
Participants who do not attend the pharmacy for seven 
consecutive days will be discontinued from the study since 
they will be deemed to have discontinued their course of 
DAA treatment and will have had their OST prescription 
suspended.
Participants are likely to be retained within the study 
through the mechanism of daily attendance for receipt 
of supervised OST; this is a powerful mechanism making 
people return to the pharmacy. It is intended that data will 
still be collected on participants who may not complete 
their course of treatment, since partial completion may 
produce an SVR also.
The primary study outcome (SVR 12 weeks after treat-
ment completion) is assessed by DBST in the pharmacies 
for both study arms.
outcomes and measures
The denominator for the outcomes on treatment uptake 
is the number of people using OST at the pharmacies 
participating in the respective arms. For the primary 
outcome, the numerator will be the number of patients 
with SVR at 12 weeks post-treatment completion (SVR12) 
after allocation to treatment arm, measured through a 
test for the presence of HCV RNA (PCR).
For the secondary outcomes on treatment uptake, the 
numerators are the number of patients who (1) Undergo 
HCV testing. (2) Initiate HCV treatment. (3) Complete 
the 12-week HCV course. (4) Number of patients with 
SVR at 12 months (to assess the impact of potential 
reinfection).
Study schedule
For both arms, screening for HCV by DBST is under-
taken prior to recruitment (t0); participant consent (t1) is 
followed by 8 weeks or 12 weeks of treatment according to 
HCV genotype (t12), 12 weeks post-treatment a final SVR 
test is taken to determine the study outcome (tend point)
Sample size
Approximately 22 000 patients are prescribed OST across 
Scotland.26 Around 85% of these patients receive daily or 
regular supervision of their OST consumption through 
one of the 1200 community pharmacies. It is expected 
that at least 40% of these patients will be infected with 
HCV, and that around 46% and 48% of infections will be 
with genotype 1 and genotype 3, respectively.9 The phar-
macies acting as cluster sites for this trial have around 1800 
patients attending for supervised OST administration. 
Sixty community pharmacies based around five study sites 
within Scottish NHS boards, will be coordinated through 
the Tayside Clinical Trials Unit (TCTU) of the Tayside 
Medical Science Centre, University of Dundee.
As the pharmacy-led pathway is a specific popula-
tion-based intervention, the number of patients on OST 
treatment at each pharmacy will be the denominator 
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for calculating DBST uptake. HCV infection status of all 
the OST patients in the denominator population is not 
known. National data repeatedly show approximately 
40% of patients on OST are HCV-positive. As this is a 
randomised trial, it can be assumed that the rate of HCV 
positivity in the OST patients/pharmacies randomised 
to the pathways should be the same. The study will be 
powered through rates of HCV therapy offered. Approx-
imately 3% of HCV-positive OST patients enter HCV 
therapy per year via conventional pathways, with 2.5% of 
the total eligible population achieving SVR per annum. 
If it is estimated that the new pathway increased this to 
15%, a sample in each arm of 141 (2N=282) will give 
90% power at the significance level. The clustered design 
requires inflation to account for intracluster correlation, 
so if the average infected subjects per pharmacy is 12, 
the inflation factor for sizes of cluster, assuming an intra-
cluster correlation of 0.05, is 1. 55. This leads to a need 
for 2n=437.
The sample of 60 pharmacies with an average of 30 OST 
patients per pharmacy gives 1800 OST patients; assuming 
40% are HCV-positive gives 700 to 800 potential patients 
for the study. This gives significant protection against any 
changes in baseline SVR success rates, and against phar-
macy dropouts or local issues that prevent an enrolled 
pharmacy from participation. This is a trial of a pathway 
so all eligible patients are the denominator for the power 
calculation, not the patients who actually enter the 
pathway and are treated.
The randomisation of the pharmacies will be stratified 
by the associated hub centre. As the end point of the 
study is the effectiveness of the pathway, any dropouts are 
part of the study outcomes, so there is no need to increase 
the sample size to allow for a dropout rate.
Data collection, management and analysis
Analysis of the trial will follow the principles outlined in 
the ICH E9 ‘Statistical Principles for Clinical Trials’ and 
carried out by the UK Clinical Research Collaboration 
(UKCRC) registered Tayside TCTU. Prior to data lock an 
agreed statistical analysis plan will be finalised covering 
the prespecified statistical analysis.
The primary outcome of SVR will be assessed as a 
binary outcome for subjects and so will use logistic regres-
sion modelling. The numerator will be the number of 
subjects achieving SVR at 12 weeks and the denominator 
will be total number of patients using OST and having 
an HCV infection diagnosed at the participating pharma-
cies. Additionally results will be expressed as a propor-
tion of the estimated HCV-infected subjects on OST. The 
estimated number of infected patients will be based on 
national survey data and the empirical rate discovered 
in the trial (allowing for patients who refuse testing). In 
order to account for the clustered nature of the trial, a 
mixed-effects logistic regression model will be used with 
the parameter indicator of the trial arm in the model 
and a random parameter to account for within-cluster 
correlation as well as stratified by hub. As all patients will 
have either achieved SVR or not, and we will assume that 
dropouts/lost to follow-up are failures, there will be no 
missing data in the primary outcome. Extrabinomial vari-
ability or overdispersion will be examined in the logistic 
model and, if present, alternative modelling such as nega-
tive binomial models will be considered. This will also be 
adjusted by therapy and genotype; the two factors are 
interdependent determining length of therapy.
Secondary binary outcomes will be analysed by the same 
procedure, initially as intention to treat with all eligible 
patients as the denominator and then exploring the steps 
in the pathway by per protocol analysis in particular to 
analyse treatment success:
 ► Proportion of HCV tested: within the duration of the 
study of those attending pharmacy sites for OST, for 
the conventional and for the pharmacist-led arms.
 ► Proportion that initiate HCV treatment within the 
duration of the study of those identified with HCV, 
for the conventional and for the pharmacist-led arms.
Proportion of those initiating treatment that complete 
the course: Multiple logistic regression modelling will 
explore the patient and pharmacy characteristics that 
are associated with the secondary and primary outcomes. 
Patient outcomes considered will be:
 ► Age.
 ► Gender.
 ► Deprivation.
 ► Employment.
 ► Comorbidity.
 ► Psychosocial variables assessed.
Pharmacy characteristics considered will be:
 ► Geographical location.
 ► Type of pharmacy service.
 ► Size of OST population.
Determination of re-infection: As the determination of 
possible re-infection is an important and stated secondary 
outcome in this study, all patients will be invited to consent 
for a further DBS HCV PCR 1 year after end of therapy 
or at end of the study, whichever is first. Those patients 
who achieve SVR will be invited to participate at their 
pharmacy. People prescribed OST are retained in the 
service for many years, since their progress of recovery 
and becoming drug-free is slow. In addition, movement 
out of Dundee, which is relatively geographically isolated, 
is minimal. We are therefore confident that we can iden-
tify all patients still in receipt of a prescription for OST 
and invite them to be re-tested for hepatitis C. Since the 
network of pharmacies providing OST is also trained to 
provide testing, we believe this is feasible.
Data management
An Excel database will be used to hold the study-related 
data. This will be managed and controlled by the coordi-
nating pharmacist in NHS Tayside with site-specific data 
being transcribed from a paper case report form (CRF) 
formulated in line with the Excel database, with the 
study protocol and in line with the requirements of the 
investigators. Development and validation of the study 
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database, quality control and extraction of data will be 
done according to study sponsor procedures. Extracts for 
analysis will be based on the data tables provided by the 
study team.
Health economic assessment
Economic analysis will be undertaken alongside the trial, 
using the costs, resource use and effectiveness data gener-
ated within the trial. The number of SVRs achieved at the 
end of the trial will be combined with the cost data to 
calculate the incremental cost per cure. A longer-term 
analysis incorporating the cost and benefits of potential 
lifetime gains through citizenship will be undertaken.
Qualitative assessment
The qualitative research will take the form of a process 
evaluation building on previous exploratory and prepara-
tory work.22 It will contribute to the assessment of the feasi-
bility and acceptability to service users and providers of a 
pharmacy-led testing and treatment pathway (including 
identification of barriers and facilitators and unintended 
consequences of participation).
Interviews will be conducted with small samples of 
(1) Consenting study participants. (2) Professionals 
providing the pharmacist-led pathway by researchers at 
University of Dundee.
Qualitative interviews will be conducted with consenting 
participants and professionals using semistructured topic 
guides developed in line with the research aims. Topics 
will not be explored in a prescriptive manner but as part 
of an open discussion. This flexible format will enable 
additional salient topics and insights to emerge. In broad 
terms, the focus for the different respondent groups will 
be as follows:
One-to-one interviews with consenting participants 
(all of whom have engaged with the service) will explore 
views on issues around the delivery and promotion of the 
pharmacist-led pathway, their response to the offer and 
delivery of treatment, and any unintended consequences.
Interviews with professionals will explore issues 
around implementation of the intervention and the trial 
elements, identify challenges and ways they have been 
overcome, and perceived response among participants.
With the interviewee’s consent, all interviews and focus 
group discussions will be recorded as digital audio files, 
which will then be transcribed in full for thematic anal-
ysis. Transcripts will be organised using a thematic frame-
work based on topics specified in the topic guide and 
emerging themes identified through a process of familia-
risation with transcript texts.
Patient and public involvement
In developing the research question and outcome 
measures for study, pilot work was undertaken using 
focus groups of people prescribed OST and their carers 
to explore their experiences of using community pharma-
cies.19 The priorities and experiences of people prescribed 
OST were further evaluated through a discrete choice 
experiment, which was used to aid the design of the phar-
macy-led pathway.20 A process evaluation was employed 
as part of the development of the DBST intervention in 
pharmacies, where recipients were asked about their expe-
riences and preferences for testing for hepatitis C.21 The 
process evaluation approach was also repeated as part of 
a feasibility study in which the assessment and treatment 
of hepatitis C in this group was piloted, to further under-
stand how the intervention would be accommodated by 
participants.22 The information gained from this exercise 
has been fed back to groups of service users attending 
the local community support and harm reduction centre. 
Patients have not been involved in the recruitment to this 
study.
dIsCussIon
Liver disease has become a major cause of premature 
death in the developed world and HCV is a major contrib-
utor to this burden.27 The care of people infected with 
HCV therapy has undergone a paradigm shift due to the 
efficacy of DAA drugs and the consequent simplification of 
therapy, with highly effective treatment choices marketed 
across the world.28 However, new and more effective path-
ways of care are urgently required in order to enhance 
testing and linkage to care and treatment.16 These novel 
pathways of care need to be carefully evaluated both for 
efficacy and cost-effectiveness compared with traditional 
pathways, as well as for unintended consequences. This 
pragmatic, cluster-randomised trial can provide strong 
evidence of the effectiveness of a pharmacist-delivered 
care pathway for HCV eradication therapy in patients 
receiving OST. A comparison will be undertaken with the 
current clinical care pathway where patients are referred 
to a conventional clinic to receive their HCV treatment. 
Trial design has aimed for high applicability in design 
decisions24 and this trial is expected to directly inform the 
future organisation of care.
Harms
Regular follow-up of the participants will occur daily in 
the DOT arm during the study treatment period by a 
pharmacist familiar in the trial methodology. For those 
participants allocated to the conventional therapy, 
regular clinical follow-up will occur in line with prevailing 
conventional NHS standard of care. At each visit partic-
ipants will be monitored for expected AEs as per the 
Summary of Product Characteristics for the drug treat-
ments used in this study. This is in line with the current 
standard of care for the NHS and only AEs outside these 
criteria will formally be recorded as AEs.
Bloods for viral load would be performed as outlined 
in the study schedule, at the pre treatment visit and at 
12 weeks postcompletion of therapy, as per the attached 
study schedule. Data on testing, referral, initiation of 
(and adherence to) therapy are routinely collected for 
the HCV clinical database and these data will also be used.
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In addition baseline and end of treatment checking 
of prescribed and non-prescribed medications and drug 
use, as documented in the study concomitant medica-
tions log, will be carried out to investigate the relation-
ship between any AEs and drug interactions.
Consenting participants
Potential participants will be approached by pharmacy 
staff familiar with the trial methodology and trained in 
GCP. They will be provided with information on the study 
verbally and via the patient information sheet and be 
given at least 24 hours to consider participation.
At their return visit for screening they will be inter-
viewed by the study pharmacist and asked to sign an 
informed consent form, once they are satisfied that they 
have had adequate explanation from the pharmacist 
explaining the trial to them.
Confidentiality
The data will be collected by the researcher (treatment 
delivering pharmacist or nurse) on a paper CRF with 
subsequent transcription to electronic CRF. Electronic 
storage will be in an encrypted form on a password-pro-
tected device. The medical notes will act as source data 
for past medical history and blood results.
All laboratory specimens, evaluation forms, reports and 
other records will be identified in a manner designed to 
maintain participant confidentiality. All records will be kept 
in a secure storage area with limited access to study staff 
only. Clinical information will not be released without the 
written permission of the participant, except as necessary 
for monitoring and auditing by the Sponsor or its designee. 
The chief investigator and study staff involved with this study 
will not disclose or use for any purpose other than perfor-
mance of the study, any data, record, or other unpublished, 
confidential information disclosed to those individuals for 
the purpose of the study. Prior written agreement from the 
sponsor or its designee will be obtained for the disclosure of 
any said confidential information to other parties.
data protection
The chief investigator and study staff involved with this study 
will comply with the requirements of the Data Protection 
Act 1998 with regard to the collection, storage, processing 
and disclosure of personal information and will uphold the 
Act’s core principles. The chief investigator and study staff 
will also adhere, if appropriate, to the current version of 
the NHS Scotland Code of Practice on Protecting Patient 
Confidentiality. Access to collated participant data will be 
restricted to the chief investigator and appropriate study 
staff. Computers used to collate the data will have limited 
access measures via usernames and passwords. Published 
results will not contain any personal data that could allow 
identification of individual participants.
trial organisation
Trial management
Overall management of the trial is being provided by 
TCTU, a UKCRC-registered clinical trials unit. A study 
clinical trial manager supported by a study coordinator 
will oversee the study and will be accountable to the chief 
investigator. They will be responsible for checking CRFs 
for completeness, plausibility and consistency. However, 
this remains the overall responsibility of the chief inves-
tigator. Any queries will be resolved by the chief investi-
gator or a delegated member of the study team.
A study-specific delegation log will be prepared for the 
study at each site, detailing the responsibilities of each 
member of staff working on the study.
A trial steering committee will be established to oversee 
the conduct and progress of the study. The steering 
committee will include the investigators above, as well as 
the NHS Tayside Director of Pharmacy and a representa-
tive from the Chief Pharmaceutical Officer's team of the 
Scottish Government. The steering committee will take 
all executive decisions. The responsibility of the steering 
committee is to ensure the scientific integrity and quality 
of the project. To achieve this, the specific responsibil-
ities of the steering committee include: maintaining 
adherence to the study protocol; approving changes to 
study protocol if required; reviewing quality assurance 
indicators; monitoring study recruitment and the overall 
study timetable; advising, as required, on specific scien-
tific items that may arise; compliance with legislation; 
adherence to research governance; reporting to funders; 
approving publication and dissemination strategies. The 
steering committee will meet every 6 months.
trial status
Recruitments commenced in December 2016. On 9 
October 2017, 234 were consented to the trial.
reporting guideline
SPIRIT 2013 statement: defining standard protocol 
items for clinical trials http:// annals. org/ aim/ article/ 
1556168/ spirit- 2013- statement- defining- standard- 
protocol- items- clinical-trials.
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